Alchemia Ltd. screams to a halt

Trading in Alchemia Ltd. (ASX:ACL) was halted. A capital raising announcement is likely, as it is short of cash and burning through it fast. Alchemia won't make it to profitability without a cash injection for it's P III trial of HA-Irinotecan.

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Trading in Alchemia Ltd. (ASX: ACL) was halted this morning. A capital raising announcement is likely, as it is short of cash and burning through it fast. Alchemia won't make it to profitability without a cash injection.

From the horse's mouth…

Alchemia is seeking the trading halt to assist in managing its disclosure obligations in relation to the proposed capital raising and maintaining an orderly market in the trading of the company's shares and to ensure that trading does not take place in an uninformed market.

The Phase III trial of Alchemia's oncology program, HA-Irinotecan, for the treatment of colorectal cancer, has started recruiting patients so cash burn will skyrocket again.

One key to valuing Alchemia is a good estimation of revenue from its approved generic drug, Fondaparinux.

Generics typically achieve a 30% market share. In late October Alchemia announced that since launching a few months ago Fondaparinux has gained a market share of around 10%. Alchemia expects manufacturing volume and market share to increase in the coming months.

Profits from Fondaparinux will begin rolling in next year, after its partner Dr Reddy's has recouped development and registration costs.

Alchemia is a story worth digging in to. After peaking at 86 cents in July, it last traded at 27.5 cents and had a market cap of $53 million.

Thanks to Ron, for bringing this story to our attention.

Dean Morel is The Motley Fool's Investment Analyst. Dean has no position in Alchemia. The Motley Fool's purpose is to educate, amuse and enrich investors. Readers can click here for a free Motley Fool report titled Read This Before The Next Market Crash

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »